文章核心观点 - 投资者常参考华尔街分析师建议做股票买卖决策，但券商建议有局限性，可结合Zacks Rank做投资决策，对雅培股票的买入评级需谨慎 [1][2][3][6] 雅培股票券商评级情况 - 雅培平均券商建议（ABR）为1.50（1 - 5代表强烈买入到强烈卖出），接近强烈买入和买入之间，基于20家券商实际建议计算得出 [1] - 20条建议中14条为强烈买入，占70%；2条为买入，占10% [1] 券商建议的局限性 - 多项研究表明券商建议在指导投资者挑选有最大价格上涨潜力股票方面效果有限或无效果 [2] - 券商因自身利益对股票评级有强烈积极偏见，每给出一条“强烈卖出”建议会给出五条“强烈买入”建议 [2] Zacks Rank介绍 - Zacks Rank是公司专有的股票评级工具，将股票分为从强烈买入到强烈卖出五个等级，是股票近期价格表现的有效指标 [3] - Zacks Rank基于盈利预测修正，与近期股价走势强相关，且在所有券商分析师提供当年盈利预测的股票中按比例分配等级，能保持五个等级的平衡 [5] - Zacks Rank更新及时，能快速反映券商分析师盈利预测修正，而ABR可能不是最新的 [5] 雅培股票投资建议 - 雅培当前年度的Zacks共识估计在过去一个月保持在4.62美元不变，分析师对公司盈利前景看法稳定，股票近期可能与大盘表现一致 [6] - 基于共识估计近期变化幅度等四个因素，雅培获得Zacks Rank 3（持有）评级，对其相当于买入的ABR需谨慎 [6]

Abbott (ABT) closed the most recent trading day at $103.23, moving -0.19% from the previous trading session. This move lagged the S&P 500's daily gain of 1.19%. Meanwhile, the Dow gained 0.25%, and the Nasdaq, a tech-heavy index, added 1.96%.The the stock of maker of infant formula, medical devices and drugs has fallen by 2.58% in the past month, lagging the Medical sector's gain of 3.54% and the S&P 500's gain of 3.35%.The investment community will be closely monitoring the performance of Abbott in its for ...

Sundry Photography ABT stock: Wall Street loves it Readers following our writing know that we are contrarian investors and we usually bet against Wall Street ratings. However, in the case of Abbott Laboratories (NYSE:ABT) stock, we found ourselves in agreement with Wall Street. More specifically, the chart below summarizes the current sentiment on ABT stock from Wall Street analysts (and Seeking Alpha writers too). As seen, Wall Street analysts have a 'strong buy' rating on the stock, with 12 out of 24 anal ...

Abbott (ABT) ended the recent trading session at $101.74, demonstrating a +1% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.6%. Elsewhere, the Dow lost 0.86%, while the tech-heavy Nasdaq lost 1.08%.Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 5.23% over the previous month, trailing the performance of the Medical sector with its gain of 1.32% and the S&P 500's gain of 3.15%.Market participants will be close ...

Healthcare stocks to buy are booming in the U.S. due to the nation’s aging population. Spending on healthcare in the U.S. now totals $4.4 trillion, or $13,493 per person, each year — more than any other country on earth. The U.S. continues to lead in both quality of medical care and healthcare innovations, developing cutting edge technologies, pharmaceutical products and surgical procedures.For all these reasons, one might assume that all healthcare stocks are thriving — but not so. The S&P Health Care inde ...

文章核心观点 - 联邦储备局可能降息,这对于可靠的股息股来说是利好消息 [1] - 但就业市场数据显示经济基本面保持强劲,这可能导致通胀上升,不利于降息 [2] - 同时地缘政治局势不确定性加剧,可能导致投资者转向避险资产政府债券,从而使股息股更具吸引力 [3] 行业和公司总结 医疗保健行业 - 雅培实验室(ABT)是全球最大的医疗设备企业之一,提供广泛的医疗产品和服务,股息收益率为2.12% [5][6][7][8] - 美敦力(MDT)是医疗设备领域的大型企业,股息收益率为3.4%,连续47年增加派息 [27][28][29] 零售行业 - 克罗格(KR)是大型连锁超市,在经济不确定时期具有防御性,股息收益率为2.19%,连续18年增加派息 [10][11][12][13] - 家得宝(HD)是家居装修零售商,在房地产需求增加时受益,股息收益率为2.77%,连续15年增加派息 [14][15][16][17] 电信行业 - 康卡斯特(CMCSA)是大型媒体和电信公司,受益于旅游业复苏,股息收益率为3.22% [19][20][21][22] 公用事业行业 - 森宝(SRE)是多元化公用事业公司,主要服务于加州南部地区,股息收益率为3.27%,连续21年增加派息 [23][24][25][26] 能源行业 - 金德摩根(KMI)是能源管道和终端运营商,尽管面临清洁能源转型,但仍具有长期价值,股息收益率为6.03% [30][31][32][33]

The bull market continues; markets quickly dusted off the 5% correction in April and soared to new highs. With too much cash on the sidelines, every shallow correction has become a buying opportunity. Blue-chip stocks are one way to play this positive momentum.From a historical perspective, the markets are in great shape for continued gains. In the first 100 trading days of 2024, the S&P 500 has had about a 10% gain. JPMorgan Wealth Management noted that since 1950, that has meant a stronger second half, wi ...

Abbott (ABT) closed at $103.95 in the latest trading session, marking a -0.27% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.7%. At the same time, the Dow added 0.01%, and the tech-heavy Nasdaq gained 1.1%.Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 2.46% over the previous month, trailing the performance of the Medical sector with its gain of 3.27% and the S&P 500's gain of 4.03%.Analysts and investors alike will be keepin ...

Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s solid sales trajectory is encouraging and should continue to sustain with several new growth opportunities. Strong potential in the Diagnostics space is highly promising as well.However, the company faces challenges from lower demand for COVID-19 testing, which is hurting growth, as well as adverse currency mov ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (ABR) of 1.53, on a scal ...